Navamedic AB — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
OraFID dosing device, Levodopa/Carbidopa minitablets delivered via OraFID dosing deviceFlexilev is a Parkinson's disease medicine made of small, dissolvable tablets containing low doses of levodopa and carbidopa, allowing doses to be adjusted in small, precise steps. OraFID is a new mechanical device that dispenses the exact number of tablets needed, with better than 99% accuracy, in amounts from 1 to 20 tablets. An optional companion app, Levilog, reminds patients when to take their dose and records how much medicine (tablets and milligrams) was taken. This 12-week study will mainly assess how acceptable this treatment routine is and how well patients stick with it when using Flexilev with the OraFID device and app. It will also evaluate the treatment's efficacy, safety, and tolerability.	Parkinson	Phase 4	À vérifier	Sweden	À vérifier
OraFID dosing device, Levodopa/Carbidopa minitablets delivered via OraFID dosing deviceFlexilev is a Parkinson's disease medicine made of small, dissolvable tablets containing low doses of levodopa and carbidopa, allowing doses to be adjusted in small, precise steps. OraFID is a new mechanical device that dispenses the exact number of tablets needed, with better than 99% accuracy, in amounts from 1 to 20 tablets. An optional companion app, Levilog, reminds patients when to take their dose and records how much medicine (tablets and milligrams) was taken. This 12-week study will mainly assess how acceptable this treatment routine is and how well patients stick with it when using Flexilev with the OraFID device and app. It will also evaluate the treatment's efficacy, safety, and tolerability.	Parkinson	Phase 4	À vérifier	Sweden	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
OraFID dosing device, Levodopa/Carbidopa minitablets delivered via OraFID dosing device	Parkinson	Phase 4	NCT07839793	FLORA — A 12-Week Study of Flexilev With the OraFID Device and App in Parkinson's Patients	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.